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In Brief
The interaction between K-Ras and
calmodulin (CaM) modulates tumor
formation through inhibition of CaM
kinase activity and suppression of Fzd8-
mediated Wnt/Ca2+ signaling. This
interaction does not occur with H-Ras or
N-Ras, and disruption of the K-Ras-CaM
interaction by the orally active natural
product prostratin represses tumor
growth.
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K-Ras and H-Ras share identical effectors and have
similar properties; however, the high degree of
tumor-type specificity associated with K-Ras and
H-Ras mutations suggests that they have unique
roles in oncogenesis. Here, we report that onco-
genic K-Ras, but not H-Ras, suppresses non-canon-
ical Wnt/Ca2+ signaling, an effect that contributes
strongly to its tumorigenic properties. K-Ras does
this by binding to calmodulin and so reducing CaMKii
activity and expression of Fzd8. Restoring Fzd8 in
K-Ras mutant pancreatic cells suppresses malig-
nancy, whereas depletion of Fzd8 in H-RasV12-trans-
formed cells enhances their tumor initiating capacity.
Interrupting K-Ras-calmodulin binding using ge-
netic means or by treatment with an orally active pro-
tein kinase C (PKC)-activator, prostratin, represses
tumorigenesis in K-Ras mutant pancreatic cancer
cells. These findings provide an alternative way to
selectively target this ‘‘undruggable’’ protein.INTRODUCTION
H-Ras, N-Ras, and K-Ras genes are frequently mutated in hu-
man tumors and affect a multitude of cellular processes. They
share a high degree of sequence homology as well as identical
regulators and effectors. However, they may also have unique
roles in physiological and pathological processes. K-Ras muta-
tions occur at high frequency in pancreatic and colorectal
cancers and in lung adenocarcinomas, while N-Ras and H-Ras
mutations are far less common (Prior et al., 2012). Furthermore,
K-Ras deficiency results in embryonic lethality, whereas N- and
H-Ras knockout mice develop normally (Johnson et al., 1997;
Koera et al., 1997; Malumbres and Barbacid, 2003). In a model
of tumor initiation and differentiation, K-Ras, but not H-Ras or
N-Ras, initiated tumors through a mechanism involving stem
cell expansion (Quinlan et al., 2008). H-Ras can replace K-Ras
when expressed from the endogenous K-Ras locus, suggesting
that the genetic locus is more important than the isoform of Ras
that is expressed (To et al., 2008). However, tumors driven by
K-Ras are more metastatic than those driven by H-Ras (Wong
et al., 2013). Together, these data suggest a potentially unique
role for K-Ras in tumor biology. Here, we report that oncogenicCK-Ras uniquely elicits a tumorigenic phenotype through down-
regulation of non-canonical Wnt/Ca2+ signaling. Binding of
calmodulin (CaM) to K-Ras, but not to H-Ras or N-Ras, appears
to be responsible for this major difference. These data provide an
alternative avenue to inhibit this ‘‘undruggable’’ protein. Indeed,
treatment of mice with prostratin, a natural product that pro-
motes dissociation of K-Ras from CaM, suppressed tumori-
genesis in pancreas cancer models and papillomas driven spe-
cifically by oncogenic K-Ras.
RESULTS
K-RasV12 and H-RasV12 Differ in Tumor Initiation Despite
Comparable Canonical MAPK and Akt Signaling
To identify distinct properties of H-Ras and K-Ras, we expressed
oncogenic H-Ras and K-Ras(4B) in NIH/3T3 cells and looked
for phenotypic differences. However, H-RasV12- and K-RasV12-
transformed cells had almost identical phenotypes: similar mor-
phologies, comparable levels of GTP-loaded Ras (Figure 1A),
similar levels of Erk (Figures 1B and S1A), and similar Akt activity
(Figures 1B and S1B).
Next, we examined their ability to self-renew at the single-cell
level, using a sphere-forming assay (Fang et al., 2005; Fujii et al.,
2009; Gou et al., 2007; Ponti et al., 2005; Singh et al., 2003). With
limited numbers of seeded cells, K-RasV12-transformed NIH/3T3
cells showed significantly increased sphere-forming efficiency
compared with H-RasV12 (Figure 1C). Re-plating revealed that
spheres from K-RasV12-transformed cells were viable and able
to re-initiate exponentially growing cells in 2D culture, whereas
H-RasV12-transformed cells were not (Figure S1C).
We next evaluated their tumorigenic potential, using limited
and serial transplantation (Clarke et al., 2006). When 1,000 cells
were engrafted subcutaneously, H-RasV12 and K-RasV12 tumors
arose at similar rates. However, when the number was reduced
to 100, K-RasV12-transformed cells displayed enhanced tumor
initiating rates compared to H-RasV12 cells (Figure 1D, left). We
then re-transplanted cells from primary tumors into a second
cohort of mice. Upon injection of 500 K-RasV12 cells, all ten injec-
tions gave rise to tumors. In contrast, only two out of ten injec-
tions of H-RasV12 cells initiated tumors (Figure 1D, right).
To examine whether K-Ras and H-Ras play distinct roles in
inducing tumorigenicity in human cancers, we first examined
their roles in BxPC3 cells, a pancreatic cancer-cell line ex-
pressing wild-type H-Ras and K-Ras. Knock down of K-Ras,
but not H-Ras, significantly reduced sphere-forming efficiency
in response to EGF and reduced the size of initiated spheresell 163, 1237–1251, November 19, 2015 ª2015 Elsevier Inc. 1237
Figure 1. K-RasV12 and H-RasV12 Have Differential Tumor-Initiating Properties, Despite Comparable Canonical Signaling Outputs
(A) Comparable levels of total Ras proteins and GTP-bound Ras as measured by Raf-RBD or Ral-GDS-RBD pull-down assays.
(B) Comparable levels of phosphorylated Erk and Akt in cells transformed by H-RasV12 or K-RasV12.
(C) K-RasV12-transformed NIH/3T3 cells presented increased sphere formation. Top: morphology of spheres formed. Bottom: sphere formation efficiency (n = 6).
(D) The tumor initiating abilities of H-RasV12-transformed and K-RasV12-transformed NIH/3T3 cells when the number of injected cells was 1,000 (top left) or 100
(top right). K-RasV12-transformed cells presented increased tumor initiating capacity, in comparison with H-RasV12-transformed cells, when the number of cells
injected became limited (bottom table). Right: cells derived from K-RasV12 driven tumors had enhanced tumor recapitulating ability than H-RasV12.
(E) Promotion of BxPC3 sphere formation by EGF. Top: morphology of spheres formed. Bottom: sphere formation efficiency as calculated by the number of
spheres normalized by the number of cells seeded (n = 6).
(F) Knockdown of K-Ras, but not H-Ras, attenuated EGF stimulation of BxPC3 sphere-forming efficiency (n = 6).
(legend continued on next page)
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(Figures 1E, 1F, and S1D–S1F). We next determined whether
oncogenic K-Ras is required for the maintenance of ‘‘stem-
ness’’ in human pancreatic tumor cells PANC2.13 and PANC1,
both of which express oncogenic K-Ras. Upon knock down of
K-Ras, both cell lines showed a differentiated morphology,
reduced expression of CD44 and CD24 (Figures S1G–S1I), and
reduced ability to form spheres with re-plating potential (Figures
1G and S1J). PANC1 is K-Ras-independent in 2D culture (Scholl
et al., 2009; Singh et al., 2009;Wei et al., 2012). However, using a
limited number of transplanted cells, K-Ras knockdown signifi-
cantly reduced their rate of tumor initiation (Figure 1H), suggest-
ing that oncogenic K-Ras mediates tumorigenicity through a
function, distinct from its role in maintaining viability in 2D.
K-Ras Suppresses Frizzled 8 and CaMKii Activity
We next investigated the mechanisms through which K-Ras
promotes tumorigenicity and stem-ness more efficiently than
H-Ras, despite comparable levels of canonical Ras signaling.
We used PCR arrays to profile stem cell-related gene expression
mediated by K-Ras or H-Ras (Figure 2A; Tables S1 and S2).
Three stem cell-related genes were expressed with a >4-fold
change between H-RasV12- and K-RasV12-transformed NIH/
3T3 cells (Figure 2B; Table S2): Bmpr1b was upregulated in
K-RasV12-transformed cells, whereas Gli2 and Frizzled 8 (Fzd8)
were downregulated. We did not pursue bmpr1b due to its low
expression, or Gli2, because it plays different roles in mouse
and human cells (Sasaki et al., 1999).
Frizzled proteins are G protein-coupled receptors involved in
Wnt signaling. Fzd1, Fzd4, and Fzd10 activate the canonical
Wnt/b-catenin pathway, whereas, Fzd8 is a major mediator of
non-canonical Wnt/Ca2+ signaling in stem cells (Sugimura
et al., 2012). The non-canonical Wnt/Ca2+ pathway involves
activation of CaMKii and the transcription factor NF-AT and inhi-
bition of b-catenin/TCF signaling (Saneyoshi et al., 2002; Seme-
nov et al., 2007; Sugimura and Li, 2010). Figure 2C confirms
that Fzd8 was downregulated in K-RasV12-transformed cells
compared with H-RasV12-transformed cells and vector controls.
K-RasV12-transformed cells also had reduced levels of acti-
vated CaMKii, as indicated by phosphorylation at Threonine-
286 (Figure 2C). Activation and nuclear translocation of NF-AT
was reduced in NIH/3T3-K-RasV12 cells (Figure 2C). The phos-
phorylated form of b-catenin was also reduced in these cells
(Figure 2C).
The non-canonical Wnt/Ca2+pathway and CaMKii suppress
canonical Wnt signaling by blocking b-catenin/TCF4 interaction
(Semenov et al., 2007; Sugimura and Li, 2010). In K-RasV12-trans-
formed cells, where CaMKii was barely phosphorylated, the
b-catenin/TCF4 interactionwas significantly increasedcompared
with H-RasV12-transformed cells, in which CaMKii activity was
elevated (Figure 2D). Furthermore, reduced activation of CaMKii
and NF-AT in NIH/3T3-K-RasV12 cells led to increased nuclear
localization of b-catenin, whereas in vector controls and NIH/(G) Knockdown of mutant K-Ras repressed PANC1 sphere formation efficiency. T
PANC1 with K-Ras shRNA expression formed spheres in smaller sizes and num
(H) Knockdown of mutant K-Ras reduced PANC1 tumor-initiating capacity. Left:
NS, no significance. *p < 0.05; ***p < 0.001; ****p < 0.0001.
See also Figure S1.
C3T3-H-RasV12 cells, in which CaMKii and NF-AT were highly acti-
vated, nuclear b-catenin was barely detectable (Figure 2C). TOP-
Flash assay confirmed that the transcriptional activity ofb-catenin
was greatly elevated in NIH/3T3-K-RasV12 cells (Figure 2E).
Consequentially, the mRNA expressions of b-catenin-target
genes, c-Myc and TCF1, were upregulated in K-RasV12-trans-
formed cell in comparison with control or H-RasV12-transformed
cells (Figure S2A).
Next, we asked whether non-canonical Wnt/Ca2+ signaling
differs in tumors driven by H-Ras or K-Ras in vivo. We compared
tumors from wild-type mice with tumors from a genetically
engineered mouse model devoid of endogenous H-Ras, but
expressing wild-type H-Ras from the endogenous K-Ras
locus. K-Ras or H-Ras mutations were then induced by topical
treatment with 7,12-dimethylbenz[a]anthracene/12-O-tetrade-
canoylphorbol-13-acetate (DMBA/TPA). Thismodel allows com-
parison of K-Ras and H-Ras oncogenes under control of the
same endogenous regulatory elements in the same cellular
background (Potenza et al., 2005; To et al., 2008). Figure 2G
shows that mutant H-Ras driven skin tumors had elevated level
of Fzd8 protein and increased levels of phosphorylated-CaMKii
compared to skin tumors with K-Ras mutations This shows
that this unique K-Ras-mediated signaling cannot be recapitu-
lated by H-Ras even when it is knocked in at the K-Ras locus.
Canonical and non-canonical Wnt signaling pathways are
both regulated by binding of WNT ligands to frizzled recep-
tors. WNT3a preferentially activates Wnt/b-catenin signaling,
whereasWNT5a activates non-canonical Wnt signaling (Weekes
and Winn, 2011). To assess whether different WNT ligands are
involved in modulating the distinct Wnt/Ca2+ signaling activities
of oncogenic H-Ras and K-Ras, we evaluated the expression
levels and functions of WNT-5a and WNT-3a in RasV12-trans-
formed NIH/3T3 cells. As shown in the Figure S2B, oncogenic
RasV12-transformed cells expressed more WNT-3a and WNT-
5a protein than control cells, but there was no difference in
expression levels between H-RasV12 and K-RasV12. Further-
more, addition of WNT ligands did not alter CaMKii activity,
b-catenin/TCF/LEF transcriptional activity, or sphere-forming
efficiency in H-RasV12 or K- RasV12-transformed cells (Figures
S2C–S2E). The divergence between H-Ras and K-Ras in non-
canonical Wnt/Ca2+ signaling is therefore not dependent upon
the presence of WNT ligands.
We next determined the effect of K-Ras on non-canonicalWnt/
Ca2+ signaling in human cancer-derived cell lines. In PANC2.13
cells, K-Ras knockdown increased Fzd8 expression, increased
phosphorylation of CaMKii (Figure 2H), and reduced b-catenin
activity (Figure 2I). We therefore conclude that oncogenic
K-Ras, but not H-Ras, represses Fzd8 expression and CaMKii
activity, amajor effector of theWnt/Ca2+ pathway, in bothmouse
fibroblasts, mouse tumors, and in human cancer cells.
Canonical Wnt/b-catenin signaling is modulated by the
non-canonical Wnt/Ca2+ pathway in K-RasV12-transformed cellsop left: western blot confirmed the knockdown efficiency. Bottom left and right:
bers when compared to vector control (n = 6).
tumor free survival curve. Right: tumor formation frequency.
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Figure 2. K-Ras, but Not H-Ras, Suppresses Fzd8
(A) Heat map of stem cell factors differentially expressed in H-RasV12 and K-RasV12-transformed NIH/3T3 cells as evaluated by qPCRarray (n = 3).
(B) Scatter plot (left) and identification of Bmpr1b, Fzd8, and Gli2 as genes differentially expressed in H-RasV12 and K-RasV12-transformed NIH/3T3 cells.
(C) Reduced Fzd8 expression andWnt/Ca2+ signaling in K-Ras-transformed NIH/3T3 cells when compared with the vector control or H-RasV12-transformed cells
(Top eight panels) and in mouse PDAC cells with oncogenic K-Ras mutation when compared with those with mutant Raf (Bottom four panels).
(D) Increased TCF4 and b-catenin complexes in K-RasV12-transformed NIH/3T3 cells (Top panel) and in mouse PDAC cells with K-Ras mutations (Bottom panel)
when compared to those with H-Rasv12 or B-Raf, respectively.
(E) Increased TCF/b-catenin activities in K-RasV12-transformed NIH/3T3 cells as compared to the vector control or H-RasV12-transformed cells (n = 4).
(F) Knockdown of K-Ras led to increased Fzd8 expression at mRNA level in PANC2.13 and PANC1 cells (n = 3).
(G) Reduction in the levels of Fzd8 expression and CaMKii phosphorylation in skin tumors harboring WT H-Ras KO with mutations in either Kras or HrasKI alleles.
(legend continued on next page)
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and in pancreatic cancer cells containing oncogenic K-Ras
(above). This suggests that activation of canonicalWnt/b-catenin
may be responsible for stem-like properties induced by K-Ras.
However, in colorectal cancers, the canonical Wnt/b-catenin
signaling pathway is strongly activated through inactivation of
the APC gene or mutation of b-catenin potentially rendering
K-Ras irrelevant with regard to stem-ness in these cells. Knock
down of K-Ras promoted expression of Fzd8 and the activation
of NF-AT and CaMKii in multiple colon cancer cell lines regard-
less of the status of wild-type or mutant APC (Figure S3A). As
expected from our model, knock down of K-Ras significantly
repressed b-catenin/TCF/LEF transcriptional activity in SW480
(mutant APC), which express wild-type b-catenin, yet not in
either HCT15 (mutant APC) or HCT116 (wild-type APC) that
have a gain-of-function mutation in b-catenin (Figure S3B). How-
ever, although repression of K-Ras expression by short hairpin
RNA (shRNA) did not alter b-catenin/TCF/LEF transcriptional ac-
tivity, or even the proliferation rates, in HCT15 and HCT116 cells,
it still inhibited their sphere formation ability in 3D culture (Figures
S3C and S3D). Therefore, K-Ras-mediated stem-ness is inde-
pendent from canonical Wnt/b-catenin/TCF/LEF transcriptional
activity. To confirm this, we treated NIH/3T3 cells transformed
by H-RasV12 or K-RasV12 with the tankyrase inhibitors JW55
and JW67 and with cardionogen1. JW55 and JW67 function as
potent inhibitors of canonical Wnt/b-catenin signaling pathway
by degrading b-catenin, and cardionogen1 inhibits the b-cate-
nin/TCF/LEF transcriptional activity. Tankyrase inhibitors
repressed b-catenin/TCF/LEF transcriptional activity in RasV12-
transformed cells (Figure S3E), but this did not affect their growth
in 3D culture and formation of spheres (Figure S3F). These sug-
gest that b-catenin/TCF/LEF transcriptional activity is affected
by non-canonical Wnt/Ca2+ signaling activity, but K-Ras driven
stem-ness is independent from the canonical Wnt/b-catenin
signaling pathway and b-catenin/TCF/LEF activation.
Inhibition of CaMKii Enhances Sphere Formation
by H-RasV12 Cells
To determine whether suppression of CaMKii observed in K-Ras-
transformed cells is responsible for the acquisition of stem-ness
properties, we treated NIH/3T3-H-RasV12 with KN-93, a selective
CaMKii inhibitor (Figure 3A). Inhibition of CaMKii reduced Fzd8
expression (Figure 3B) and increased b-catenin transcriptional
activity, confirming the inhibitory effects of Wnt/Ca2+/CaMKii
signaling on the canonical Wnt pathway (Figure 3C). Moreover,
KN-93 treatment enhanced the sphere-forming efficiency and
thesizeofspheroidcolonies inNIH/3T3-H-RasV12cells (Figure3D).
Downregulation of CaMKii activity is therefore essential for induc-
tion of malignant features observed in K-Ras-transformed cells.
Knockdown of Fzd8 Induces Tumorigenicity
in H-RasV12 Cells
To further determine the role of Fzd8 in Wnt/Ca2+ signaling, we
knocked Fzd8 down in NIH/3T3-H-RasV12 cells (Figures 3A and(H) Knockdown of K-Ras increased Fzd8 protein level, non-canonical Wnt signa
(I) Knockdown of K-Ras in PANC2.13 cells reduced canonical Wnt signaling as r
*p < 0.05; **p < 0.01.
See also Figures S2 and S3 and Tables S1 and S2.
C3E). We observed reduced phospho-CaMKii level and enhanced
b-catenin activity (Figures 3E and 3F). Formation of spheres with
re-plating ability was also enhanced upon Fzd8 knockdown
(Figure 3G). Importantly, mice injected subcutaneously with
50 NIH/3T3-H-RasV12 cells showed significantly reduced tu-
mor-free survival following shRNA suppression of Fzd8 (Fig-
ure 3H). Thus, suppression of Fzd8 expression pheno-copies
the effects of oncogenic K-Ras in these stem-ness assays.
Roles of Fzd8 in K-Ras-Driven Malignancy
Next, we tested whether downregulation of Fzd8 is required
for NIH/3T3-K-RasV12 cells to promote tumor formation. Resto-
ration of Fzd8 expression in NIH/3T3-K-RasV12 cells enhanced
levels of phosphorylated CaMKii (Figure 4A) and reduced b-cat-
enin/TCF/LEF activity (Figure 4B). Furthermore, restoration of
Fzd8 significantly reduced sphere formation in NIH/3T3-
K-RasV12 cells (Figure 4C). Fzd8 overexpression also abolished
tumor formation in nude mice (Figure 4D). Interestingly, exoge-
nously added WNT3a or WNT5a ligand did not affect the
increased phospho-CaMKii and inhibited b-catenin activity
caused by the overexpression of Fzd8 in NIH 3T3-K-RasV12 cells
(Figures S4A and S4B). These suggest that the altered Wnt/Ca2+
signaling pathway and b-catenin activity resulting of Fzd8 over-
expression cannot be rescued by canonical or non-canonical
Wnt pathway ligands.
When Fzd8 was overexpressed in PANC2.13 cells, we
observed an increase in phospho-CaMKii level, with a concur-
rent reduction in the expression of CD44 and CD24 (Figure
S4C). When compared with control cells, Fzd8-overexpressing
PANC2.13 cells displayed significant downregulation of multiple
b-catenin targeted genes, including CCND-1, LEF1, and c-Myc
(Herbst et al., 2014), consistent with repressed b-catenin tran-
scriptional activity (Figure S4D). Overexpression of Fzd8 in
PANC1 cells, resulted in elevated NF-AT transcriptional activity,
decreased activity of b-catenin, and reduced expression of
CD44 and CD24 (Figures 4E and S4E). Overexpression of
Fzd8 in these pancreatic cancer lines induced differentiation-
like morphological changes, phenocopying those observed
upon K-Ras knockdown (Figure S4F). Furthermore, nude mice
with subcutaneous xeno-transplants of Fzd8-overexpressing
PANC1 had increased tumor-free survival rates (Figure 4F).
Thus, restoration of Fzd8 expression, which enhances Wnt/
Ca2+ signaling and suppresses canonical Wnt signaling, reduces
tumor formation by K-RasV12-transformed cells or pancreatic
tumor cells possessing oncogenic K-Ras.
Human Fzd8 is normally expressed in brain, heart, kidney, and
muscle, as well as in the pancreas (Saitoh et al., 2001). Immuno-
histochemistry of four human pancreatic tissue arrays revealed
that while Fzd8 expression was abundant in normal pancreatic
acini, islet, and ductal cells, its expression was frequently lost
in malignant pancreatic adenocarcinomas (Figures 4G and
S4G). Tissue array T143, B1, B2, B5, and B6 revealed no reduc-
tion in Fzd8 expression in islet cell tumors, which are mostlyling (p-CaMKii), and increased phosphorylation of b-catenin.
evealed by TOPFlash assay (n = 4).
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Figure 3. Fzd8-Mediated Non-canonical Wnt/Ca2+ Signaling Suppresses the Tumor-Promoting Properties of H-RasV12-Transformed NIH/
3T3 Cells
(A) Schematic illustration of Fzd8 in non-canonicalWnt/Ca2+ signaling pathway and its crosstalk with canonical Wnt signaling. Small molecule, KN-93, and shRNA
against Fzd8 were used to block CaMKii activity and Fzd8 expression for following experiments.
(B) Inhibition of CaMKii by KN-93 reduced phosphorylation of CaMKii and reduced the expression of Fzd8.
(C) KN-93 treatment stimulated b-catenin transcriptional activities in H-RasV12-transformed NIH/3T3 cells (n = 4).
(D) Inhibition of CaMKii by KN-93 enhanced sphere formation in H-RasV12-transformed NIH/3T3 cells, but not in K-RasV12-transformed NIH/3T3 cells (n = 6).
(E and F) Knockdown of Fzd8 in H-RasV12-transformed NIH/3T3 cells. Reduced phospho-CaMKii levels (D) and stimulated b-catenin transcriptional activities
(n = 4) (E).
(G) Knockdown of Fzd8 in H-RasV12-transformed NIH/3T3 cells promoted sphere formation and re-plating efficiency (n = 6).
(H) Knockdown of Fzd8 in H-RasV12-transformed NIH/3T3 cells enhanced their tumor initiating abilities.
*p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 4. Downregulation of Fzd8 Is Required for K-Ras to Enhance Tumor Initiation
(A and B) Restoration of Fzd8 expression in K-RasV12-transformed NIH/3T3 cells enhancedWnt/Ca2+ signaling (A) and reduced b-catenin transcriptional activities
(B) (n = 4).
(C) Restoration of Fzd8 in K-RasV12-transformed NIH/3T3 cells reduced sphere formation and re-plating efficiency (n = 6).
(D) Restoration of Fzd8 reduced tumor initiation capacity of K-RasV12-transformed NIH/3T3 cells.
(E) Fzd8 restoration in PANC1 cells enhanced Wnt/Ca2+ signaling as revealed by NF-AT transcriptional activities (n = 4) and reduced b-catenin activities (n = 4).
(F) Fzd8 restoration reduced the tumor initiating ability of PANC1 cells.
(G) Downregulation of Fzd8 in human pancreatic tumor tissues: micrographs of tissue sections immunostained for Fzd8 in human pancreatic cancer adjacent
normal tissue and adenocarcinomas (magnification = 2003).
(legend continued on next page)
Cell 163, 1237–1251, November 19, 2015 ª2015 Elsevier Inc. 1243
benign and in which K-Ras is rarely mutated (Figure S4G). In
addition, Fzd8 expression was strongly repressed in stage I
pancreatic adenocarcinomas (Figure 4G), in which oncogenic
activation of K-Ras has most likely already occurred. H-scoring
further provided semiquantitative analysis indicating Fzd8 was
significantly repressed in human malignant pancreatic speci-
mens when compared with normal pancreases including can-
cer-adjacent normal tissues (Figure 4H; Data S1).
To further confirm the expression of Fzd8 in human pancreas
tissues, we used an in situ hybridization method, RNAscope
(Wang et al., 2012). As shown in Figure 4I, normal pancreases
and cancer-adjacent normal tissues hybridized with the probes
specifically for human Fzd8, whereas malignant pancreatic
tissue showed no detectible Fzd8 expression. Moreover,
Oncomine software (Life Technologies), showed that Fzd8 was
significantly downregulated in human pancreatic ductal adeno-
carcinomas and multiple types of human cancer (Figure S4H).
Taken together, we conclude that expression of Fzd8 is
repressed in multiple cancers and suggest it may have a role
as a tumor suppressor.Wnt/Ca2+ Signaling Is Modulated by K-Ras-Calmodulin
Interaction
Calmodulin (CaM) binds preferentially to GTP-bound K-Ras4B,
but not to H-Ras, N-Ras, or K-Ras4A (Klee and Vanaman,
1982; Schulman, 1993; Villalonga et al., 2001) (Figure 5A). This
specific interaction betweenCaMandK-Ras can change its sub-
cellular localization and thus reduce the pool of CaM available to
activate CaMKii and its subsequent non-canonical Wnt/Ca2+
signaling. The hypervariable region of K-Ras4B is essential for
CaM binding, and phosphorylation of Ser181 of K-Ras4B abol-
ishes this interaction (Lopez-Alcala´ et al., 2008; Villalonga
et al., 2001). We generated retroviruses encoding either amutant
(S181D) that mimics phosphorylation or mutant (S181A) form of
K-RasV12 that cannot undergo phosphorylation and introduced
these mutants into NIH/3T3 cells (Figure S5A). K-RasV12-
S181D did not co-immunoprecipitate with CaM, whereas wild-
type and the S181A mutant maintained interaction with CaM un-
der identical conditions (Figure 5B). K-RasV12-S181D-express-
ing cells showed increased levels of phospho-CaMKii and
marked increase in Fzd8 promoter activity, as well as increased
expression of Fzd8, in comparison with K-RasV12- or K-RasV12-
S181A-transformed cells (Figures 5C–5E). Even though they
exhibited comparable levels of K-Ras protein expression and
phospho-Erk, K-RasV12-S181D-infected NIH/3T3 cells showed
elevated levels of active CaMKii when compared with
K-RasV12- or K-RasV12-S181A-transformed cells (Figure 5E).
K-RasV12-S181D-expressing cells further showed increased
transcriptional activity of NF-AT, another major down-stream
mediator of Wnt/Ca2+ signaling pathway, and repression of
b-catenin transcriptional activity (Figure 5F). These data show
that K-Ras regulates Fzd8-mediated non-canonical Wnt/Ca2+(H) H-scores of Fzd8 immunoreactivities in pancreatic tissue arrays including no
(I) RNAscope in situ hybridization probed for human Fzd8 in cancer adjacent pan
*p < 0.05; **p < 0.01.
See also Figure S4.
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specific interaction with CaM. In contrast, oncogenic H-Ras-
transformed tumor cells contain sufficient free CaM to activate
CaMKii. N-Ras, likeH-Ras, is unable to bind toCaM (Figure S5C).
As a result, cells transformed by N-Ras resemble those trans-
formed by H-Ras, including the phosphorylation of CaMKii,
elevated expression of Fzd8, and decreased b-catenin/TCF/
LEF transcriptional activity (Figures S5D–S5F).
Taken together, these data suggest that the differential inter-
actions between CaM and Ras proteins are the key components
that distinguish down-stream CaMKii activity and Fzd8 expres-
sion and that disrupting the interaction between K-Ras and
CaM by stimulating phosphorylation of S181 is an attractive
approach to suppress oncogenic K-Ras-driven malignancy.
Phosphorylation of K-Ras by Treatment with Prostratin
Compromises Its Binding to CaM and Suppresses
Tumorigenicity
Protein kinase C (PKC) regulates K-Ras by phosphorylation of
S181 (Bivona et al., 2006). While typical phorbol esters, such
as PMA, activate PKC and promote tumor formation, an atypical
PKC activator, prostratin (12-deoxyphorbol-13-acetate), is not a
tumor promoter (Szallasi et al., 1993; Zayed et al., 1984). Here,
we determined whether this non-tumor promoting PKC activator
could be used as an anti-cancer agent to reduce K-Ras-medi-
ated malignancy (Figure 5G).
Prostratin activates PKC in a dose-dependent manner (Fig-
ure S6A) and abolishes the interaction between K-Ras and
CaM in RasV12-transformed cells and human pancreatic cancer
cell lines (Figure 5H) and increased levels of phospho-CaMKii
(Figures 5H and 5I). Prostratin also increased expression of
Fzd8 and reduced expression of the b-catenin targeted gene,
LEF1 (Figure S6B). Of note, prostratin did not alter the activity
of CaMKii in cells transformed by H-RasV12 or K-RasV12-S181D
(Figure 5I). Moreover, K-RasV12, but not H-RasV12 or K-RasV12-
S181D-transformed NIH/3T3 cells, were sensitive to prostratin
and showed dramatically reduced cell viability (Figure 5J). These
in vitro responses led us to ask whether prostratin could be used
to treat K-Ras-driven malignancies. Indeed, prostratin adminis-
tered either orally or intra-peritoneally strongly suppressed
tumorigenicity of K-RasV12-transformed cells with no evidence
of systemic toxicity (Figure S6C). A single, small subcutaneous
tumor derived from K-RasV12-NIH/3T3 cells in the presence of
prostratin showed greatly increased phospho-CaMKii compared
with vehicle control (Figure S6D).
Prostratin Suppresses Tumor Initiation and Growth of
Human Pancreatic Cancers
In response to prostratin, human pancreatic cancer cells showed
morphological changes, phenocopying those observed with
knock down of K-Ras or overexpression of Fzd8 (Figure S7A,
left panel). Moreover, treatment of prostratin significantly reducedrmal and malignant tissues.
creatic normal tissue and pancreatic adenocarcinoma.
Figure 5. CaM-KRas Interaction Is Essential for Suppression of CaMKii Activity and Fzd8 Expression in K-RasV12-TransformedNIH/3T3 Cells
(A) CaM interaction with K-RasV12, but not with H-RasV12, as revealed by CaM pull-down assay in the presence of EDTA or Ca2+.
(B) Loss of interaction between CaM with K-RasV12-S181D mutant when compared with K-RasV12 or K-RasV12-S181A mutant.
(C) K-RasV12-S181Dmutant presented reduced capability to suppress Fzd8 promoter activities when comparedwith K-RasV12 or K-RasV12-S181Amutant (n = 4).
(D) Increased Fzd8 expressions in NIH/3T3-K-RasV12-S181D cells when compared with K-RasV12 or K-RasV12-S181A group at RNA level (n = 3).
(E) K-RasV12-S181D-expressing NIH/3T3 cells showed increased levels of Fzd8 expression and phospho-CaMKii when comparedwith NIH/3T3-K-RasV12 or NIH/
3T3-K-RasV12-S181A cells. There was no significant difference in the levels of K-Ras protein and phospho-Erk among three cell lines.
(F) NIH/3T3-K-RasV12-S181D cells presented significantly increased NF-AT transcriptional activity (left) and reduced Wnt/b-catenin activity (right) when
compared with K-RasV12 or K-RasV12-S181A group (n = 4).
(legend continued on next page)
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both cell viability and proliferation rates of these cells (Figure S7A,
right panel).
To test the effects of prostratin on K-Ras-driven human
pancreatic cancers in vivo, we first asked whether prostratin
can prevent pancreatic tumor formation in a xenograft model.
As Figure 6A shows, prostratin significantly reduced the fre-
quency of tumor formation at subcutaneous sites. Moreover,
the average size of established tumors was much smaller
than tumors in the control group (Figure 6B). Pancreatic tumor
cells were labeled with luciferase for detecting tumor forma-
tion more accurately. Bioluminescence imaging (BLI) confirmed
that treatment with prostratin profoundly suppressed tumor
initiation and tumor size (Figure 6C). In addition, xenografted
pancreatic tumors treated with prostratin showed reduced tu-
mor growth rates during therapy, as well as reduced expression
of Ki67 (Figure 6D).
We next evaluated the effects of prostratin in orthotopic
models of human pancreatic cancer cells with mutant K-Ras.
PKC activity assays revealed that the oral route was preferable
for delivering prostratin efficiently into the pancreas relative to
the intraperitoneal route (Figure S6E). Immuno-compromised
NOD-SCID mice receiving daily oral treatment of prostratin had
lower tumor burden in the orthotopic sites compared to control
mice. BLI analysis revealed that prostratin reduced the sizes of
orthotopic tumors (Figures 6E and S7B). Moreover, prostratin
reduced metastasis to the peritoneum in orthotopic pancreatic
cancer models (Figures 6E and S7C). As shown in Figures 6F
and S7B, H&E staining revealed that most of prostratin-treated
mice did not show formation of primary tumors in the pancreas,
whereas mice in the control group had obvious orthotopic
tumors and normal pancreatic tissue was barely detectable.
In addition, orthotopic tumors in the prostratin-treated group
expressed much lower Ki67 (Figures 6G and S7B). Our data
suggest that prostratin significantly reduces tumor initiation
frequency of human pancreatic cancers in xenograft models.
Next, we tested the anti-tumor effects of prostratin on estab-
lished human pancreatic xenograft tumors, subcutaneously or
orthotopically transplanted into immune-compromised mice.
Daily oral prostratin treatment started around 10–14 days post-
injection, depending on the cell lines and models (Figure 7A).
Prostratin showed anti-tumor activity on human pancreatic sub-
cutaneous tumors, defined by reduced growth rate when
compared to vehicle-treated tumors (Figure 7A). Additionally,
prostratin-treated subcutaneous tumors showed enhanced
expression of cleaved caspase 3 (Figure S7D), suggesting it ex-
erts cytotoxic effects on established tumors.
Cell-free DNA (cfDNA) in the bloodstream shows a nearly
perfect correlation with primary tumor size following effective(G) Schematic illustration of CaM-K-Ras interaction in K-Ras-mediated repressio
interfere the interaction through phosphorylation of K-Ras by the activation of PK
(H) CaM interaction with K-RasV12 was suppressed by the treatments of pro
immunoblotting.
(I) Elevated activation of CaMKii by prostratin treatments in NIH/3T3 cells transfo
(J) Cell morphologies of NIH/3T3 cells transformed by K-RasV12, K-RasV12-S181
used as the vehicle control.
*p < 0.05; **p < 0.01.
See also Figures S5 and S6.
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2003). Therefore, the quantification of cfDNA can be a useful
tool for monitoring certain cancers, including pancreatic malig-
nancies (Sikora et al., 2015). Here, we used Taqman probes
specifically detecting human cfDNA in mice in which human
pancreatic cancer cells had been orthotopically implanted
(Cheng et al., 2009) (Figure 7B). The level of human cfDNA
increased more than six times above baseline on day 14 post-
tumor implantation. The concentration of human-specific cfDNA
decreased in prostratin-treated animals over time, whereas it
showed positive dynamic changes in controls (Figure 7B). These
data demonstrate that prostratin significantly represses the
burden of human pancreatic cancers in orthotopic xenograft
models.
Taken together, our data suggest that prostratin, an acti-
vator of atypical PKCs, can efficiently reduce the interaction of
K-Ras and CaM, rewireWnt/Ca2+ signaling, and suppressmalig-
nancy mediated by oncogenic K-Ras in pancreatic cancers.
Prostratin Specifically Represses K-RasG12V-Induced
Papilloma
While the xenografts described above demonstrate the potential
of human tumor cells to respond to prostratin in vivo, the effects
of the tumor microenvironment and immune system are not
recapitulated in these models. Therefore, we examined the
effects of prostratin in a genetically engineered mouse model
(GEMM). We used a papilloma model driven by oncogenic
H-Ras or K-Ras under the control of a skin stem cell promoter,
Lrig1 (Figure 7C) (Jackson et al., 2001; Jaks et al., 2010; Page
et al., 2013; Powell et al., 2012; Tuveson et al., 2004). In this
GEMM, tamoxifen-inducible Cre recombinase initiates the
expression of oncogenic H-Ras or K-Ras, inducing papillomas
during wound-healing (Figure 7C).
Starting from day 5 post-tamoxifen induction and 2 days
before wounding, daily oral prostratin treatment was adminis-
tered to Lrig1-Cre/ER/LSL/K-RasG12D and Lrig1-Cre/ER/LSL/
H-RasG12V mice (Figure 7C). Six of six Lrig1-Cre/ER/LSL-
K-RasG12D mice receiving placebo treatment had detectable
papillomas within 7 days post-wounding; however, only two of
six Lrig1-Cre/ER/LSL/K-RasG12D mice treated with prostratin
showed papilloma formation, at a delayed point in time (between
14 and 26 days post-wounding) (Figure 7D, bottom panel). In
addition, prostratin significantly reduced the invasive signatures
and the growth rate of K-RasG12D-induced papillomas (Figures
7E and S7E). Lrig1-Cre/ER/LSL/H-RasG12V mice showed no
significant difference in tumor initiation rates and tumor sizes
between control (7/9) and prostratin-treated group (8/9) (Fig-
ures 7D, S7F, and S7G). In conclusion, prostratin significantlyn of Fzd8 expression and Fzd8-promoted stem-ness. Prostratin is proposed to
C.
stratin, as revealed by CaM pull-down assay. WCB, whole cell lysate; IB,
rmed by K-RasV12, not K-RasV12-S181A mutant or H-RasV12.
A mutant, and H-RasV12 in the response to prostratin treatments. DMSO was
Figure 6. Prostratin Prevented Tumor Initiation of Human Pancreatic Cancers with Mutant K-Ras
(A) Tumor initiation rates of subcutaneously injected PANC1 and PANC2.13 in the response to either vehicle or prostratin treatments. Top panel: schematic
illustration of experimental design. Oral prostratin administration was given 1 day before tumor implantation. Nude mice were used for subcutaneous injections,
and SCID mice were used for orthotopic implantation.
(B) Tumor growth curve of the subcutaneous tumors derived from PANC2.13 in the response to drug treatments (n = 10).
(C) Bioluminescence imaging (BLI) signaling changes of the subcutaneous tumors derived from PANC2.13 in the response to drug treatments (n = 10).
(D) Tumor proliferation rate and Ki67 staining of the subcutaneous tumors derived from PANC2.13 in the response to drug treatments. Tumor proliferation rate
(D27–D36) = (size of tumor on D36  size of tumor on D27)/size of tumor on D36 3 100.
(E) Tumor initiation rate and bioluminescence imaging (BLI) signaling activity of the orthotopic tumors derived from PANC2.13 in the response to drug treatments.
(legend continued on next page)
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reduced the formation of papillomas driven by K-RasG12D,
whereas it showed no effect on H-RasG12V-induced tumors.
All the described experiments in xenograft and GEMM
models are approved by UCSF IACUC (protocol number:
AN092211-03D).
DISCUSSION
Historically, the high degree of sequence homology, coupled
with similar ability of mutant H-Ras, N-Ras, and K-Ras onco-
genes to transform cells in culture and to activate common
cellular signaling pathways, supported the idea that these three
Ras gene products are functionally redundant (Bos, 1989; Cas-
tellano and Santos, 2011; Chesa et al., 1987; Furth et al., 1987;
Leon et al., 1987). Here, we report thatH-Ras and K-Ras actually
differ in their abilities to induce tumor initiation and that this
is directly related to the ability of K-Ras to suppress the Fzd8-
mediated non-canonical Wnt/Ca2+ signaling pathway. One
consequence of suppressing this pathway is the induction of
canonical Wnt signaling. However, our data, and those of others,
suggest that this induction is not sufficient to promote malig-
nancy, at least in pancreatic tissue.
To be noted, two key down-stream effectors of non-canonical
Wnt/Ca2+ signaling, NF-AT and CaMKii, are involved in the regu-
lation of expression of multiple genes (Krebs, 1998; Rao et al.,
1997). For example, NF-AT is a transcription factor and has
been predicted to directly bind to the promoter regions of multi-
ple genes that are associated with tumorigenesis, such as TNF
and MMP9. The functions of NF-AT on down-stream genes
and their potential crosstalk with K-Ras need to be investigated
further.
CaMKii is regulated by binding to CaM (Bachs et al., 1994;
Klee and Vanaman, 1982; Stewart et al., 1982). Interestingly,
CaM also binds to K-Ras4B, but not to N-Ras, H-Ras, or
K-Ras4A (Villalonga et al., 2001). Furthermore, the binding of
K-Ras to CaM is attenuated by phosphorylation of Ser181 by
PKC. The K-RasV12 S181D variant lost the ability to suppress
CaMKii activity and Fzd8 expression, suggesting that the inter-
action between K-Ras and CaM, which is GTP-dependent, is
an important pathway for K-Ras to inhibit Fzd8-mediated non-
canonical Wnt/Ca2+ signaling. Therefore, blocking this specific
interaction between K-Ras and CaM may provide a novel
approach to target K-Ras selectively.
Here, we report that activation of PKC by prostratin leads to
the dissociation of K-Ras and CaM, activation of non-canonical
Wnt/Ca2+ signaling, and suppression of K-Ras-mediated malig-
nancy. Our finding leads to an open question: while the activation
of PKC isozymes by phorbol esters has long been considered
to promote tumorigenesis, what drives the difference between
PKC activation by prostratin and other typical activators, such
as PMA?
PKC has been implicated in tumorigenesis for over 30 years
(Castagna et al., 1982). PKC is a family of related isoforms, cate-(F) H&E staining of normal mouse pancreases and orthotopic tumors derived fro
(G) Ki67 staining of orthotopic tumors derived from PANC2.13 in the response to
*p < 0.05; **p < 0.01; ***p < 0.001. Data are means ± SEM for (B) and (C).
See also Figure S6.
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and atypical (z, l/i) (Basu and Pal, 2010), which exhibit overlap-
ping as well as opposing functions (Steinberg, 2008). For
example, PKCd is believed to function as a tumor suppressor
since downregulation rather than activation of PKCd has been
associated with tumor promotion (Lu et al., 1997). Surprisingly,
the majority of cancer-associated mutations in PKC subgroups
are loss-of-function (Antal et al., 2015), and several mutations
are dominant negative, that suppress global PKC signaling (Antal
et al., 2015). This establishes a hypothesis: PKC isozymes gener-
ally function as tumor suppressors and, therefore, anti-cancer
therapies should focus on restoring, not inhibiting PKC activity.
This suggestion had also been made by Bivona et al. (2006)
based on their observations that PKC-mediated phosphorylation
of K-Ras at Serine-181 affects K-Ras activity.
Interestingly, PMA and prostratin have been shown to differ
substantially in their biological activities (activation versus sub-
cellular translocation) on PKCa and PKCd (Ma´rquez et al.,
2008), potentially explaining their distinct properties on tumor
promotion. Moreover, although K-Ras is known to be phosphor-
ylated by PKC, the specific functions of different PKC isozymes
on the phosphorylation of S181 within the polybasic region of
K-Ras remain to be defined. Further investigation of the specific
PKC isoforms required for K-Ras phosphorylation and regulation
by prostratin will be needed to clarify these unanswered ques-
tions and to develop more potent inhibitors for blocking K-Ras-
CaM interactions.
In summary, K-Ras suppresses Wnt/Ca2+ signaling pathway
by direct binding with CaM, leading to the reduced CaMKii activ-
ity and downregulating Fzd8 expression. Downregulation of
Fzd8 expression by K-Ras leads to a sustained suppression
of Wnt/Ca2+ signaling, which causes increased tumorigenicity.
The isoform-specific activity of K-Ras, described here, can be
exploited to block K-Ras oncogenic activity without affecting
other Ras isoforms.
EXPERIMENTAL PROCEDURES
Cell Lines
NIH/3T3, BxPC3, PANC1, PANC2.13, SW480, LS180, HCT15, and HCT116
cells were from ATCC. Mouse pancreatic adenocarcinoma cells were from
Dr. Collisson (University of California, San Francisco). Mouse cell lines were
grown in DMEM with 10% FBS (or calf serum [CS] for NIH/3T3 cells) at
37C, 5% CO2. Human colon cancer cell lines were cultured in RPMI-1640
medium with 10% FBS. Human pancreatic cancer cell lines were maintained
in RPMI-1640 medium supplemented with 15% FBS and human recombinant
insulin (GIBCO 12585-014).
Animal Studies
All experiments were approved by the University of California, San Francisco
(UCSF) Institutional Animal Care and Use Committee (IACUC). RasV12-trans-
formed NIH/3T3 cells were subcutaneously injected in female nude mice
(Nu/Nu) at 50, 100, or 1,000 cells per flank. Palpable tumors were measured
twice a week. Mice were divided into five/group. Pancreatic adenocarcinoma
cells-derived KrasLSL-G12Dmice were provided by Dr. Collisson and genotypedm PANC2.13.
drug treatments.
Figure 7. Prostratin Represses In Vivo Malignancy Driven by Oncogenic K-Ras
(A) Prostratin showed anti-tumor effects on established subcutaneous tumors derived from 0.53 106 cells of PANC1 or PANC2.13 (n = 7; data are means ± SEM).
(B) Prostratin suppressed orthotopic tumor burdens measured by cfDNA values (n = 5 for PANC2.13 group; n = 6 for PANC2.03 group).
(C) Prostratin reduced the incidence of papilloma formations in LRIG1cre/ER/LSL-Rasmutant GEMM. Left: schematic illustration of the generation of papilloma in
LRIG1cre/ER/LSL-Rasmutant mice. Right: the pictures of mice carrying K-RasG12D-induced papillomas with vehicle or prostratin treatment.
(D) Prostratin affected papilloma initiation differently in LRIG1cre/ER/LSL-H- and K-Rasmutant mice.
(E) H&E staining and IHC stained for E-cadherin and vimentin in K-RasG12D-induced papillomas with vehicle (top) or prostratin treatment (bottom).
See also Figure S7.
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as described (Collisson et al., 2011; Dankort et al., 2007; Hingorani et al.,
2003). One hundred cells were orthotopically implanted in 6- to 8-week-old
FVB/n mice in 20 ml 50%Matrigel using a 28.5-gauge needle. Mice were moni-
tored for 1 month and were euthanized when distressed.
Skin tumors were induced by the two-stage chemical carcinogenesis proto-
col using DMBA and TPA (Balmain and Pragnell, 1983). Histologically
confirmed skin carcinomaswere processed formolecular analyses by conven-
tional methods. Mutations in Kras and HrasKI alleles were identified by direct
sequencing (Karnoub and Weinberg, 2008; To et al., 2008).
Prostratin for animal treatment was from Santa Cruz Biotechnology
(sc-203422A). It was administrated daily into either NOD-SCIDmice or athymic
NUDEmice by oral gavage at 1 mg/kg or intraperitoneal injection at 0.5 mg/kg.
Ten percent DMSO, 10% cremophor, and 80% saline solutions were used as
the solvent and vehicle control. The toxic effects of prostratin were evaluated
by monitoring body weight for at least 30 days.
Lrig1Cre/ER/LSL HrasG12V and Lrig1Cre/ER/ LSL-KrasG12D mice have been
backcrossed into the FVB/N background over multiple generations. Cre
recombinase was activated in both groups of mice. A single dose of 4-OH-
tamoxifen was topically applied at 8 weeks of age and on day 7. Thereafter,
papilloma development was induced by wounding the back of the mice.
DNA Extraction from Mouse Plasma Samples
All blood samples were collected in K2EDTA containing tubes (BDMicrotainer;
365974) and centrifuged at 1,500 3 g for 10 min. The supernatants were
collected from the top of the plasma to eliminate cell contamination. Plasma
was stored at 80C. cfDNA was extracted from 100 ml of plasma using
NucleoSpin Plasma XS kit (Macherey-Nagel; 740900). Quantification of hu-
man cfDNA in mouse plasma is described in the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, two tables, and one data file and can be found with this article
online at http://dx.doi.org/10.1016/j.cell.2015.10.041.
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